Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd.
CALGARY, Alberta, May 31, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. ( "Biosenta") (CSE: ZRO) announces that, further to its news release dated October 12, 2022, it has ceased negotiations with Voran Group Ventures Ltd. in respect of the previously announced Memorandum of Understanding dated October 5, 2022, for the commercialization of Biosenta's Tri-Filler® antimicrobial products in Canadian markets and worldwide.
AboutBiosentaInc.
Biosenta is a Canadian-based company that develops and manufactures a range of safe and environmentally sound chemical compounds for household and industrial applications.
Disclaimer
The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Clarivate Plc , a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligencetm. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes...
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940), today announced a...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX,...
The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all...
Regulatory News:
Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...
